PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 2511148

[Does parenteral fat administration modify immunocompetence?].

P Thul·J M Müller·H W Keller
View original source ↗Export metadata ↓

Abstract

Evidence from studies in carcinoma patients who received intravenous glucose or glucose-lipid solutions preoperatively indicates that fibrinogen, alpha-II-macroglobulin, and coeruloplasmin serum levels remain unchanged. On the other hand, parenteral administration of lipids or glucose induces an increase of IgM, IgG, IgA and complement C3 serum concentrations. Cutaneous allergy testing shows no significant difference whether only glucose was used or half of the calories were replaced by 2.4 g lipids/kg BW x day.

Explore related subjects

Antibody FormationFat Emulsions, IntravenousHumansImmunity, CellularImmunocompetenceParenteral Nutrition, TotalEnglish AbstractJournal ArticleReview

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

P Thul, J M Müller, H W Keller. 1989. [Does parenteral fat administration modify immunocompetence?].. https://pubmed.ncbi.nlm.nih.gov/2511148/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2005

Unique and shared features of Golgi complex autoantigens.

Here we summarize recent advances in the characterization of autoimmune antigens associated with the Golgi complex. All Golgi autoantigens identified to date are high molecular weight proteins rich in coiled-coil domains and localized to the cytoplasmic face of the Golgi cisternae. The characteristic features of these Golgi autoantigens are interestingly similar to selected human autoantigens reported in other intracellular compartments such as endosome, centrosome, and centromere. The implication of this class of autoantigens in autoimmunity is discussed.

Antibody Formation↗
PubMed2005

Th1-biased humoral immune responses against Wilms tumor gene WT1 product in the patients with hematopoietic malignancies.

The Wilms' tumor gene WT1 is highly expressed in leukemias and myelodysplastic syndrome (MDS), and WT1 expression levels increase along with the disease progression in chronic myeloid leukemia and MDS. We previously reported that IgM and IgG WT1 antibodies were detected with significantly higher detection rate and antibody titers in leukemias and MDS compared to those in healthy volunteers. In this study, whether IgG humoral immune responses against WT1 protein were Th1- or Th2-type were determined by measurement of four subclasses of IgG WT1 antibody, IgG1, IgG2, IgG3, and IgG4. In leukemias and MDS, Th1-type WT1 antibodies such as IgG1, IgG2, and IgG3 were significantly increased in both detection rate and antibody titers compared to those in healthy volunteers, whereas Th2-type WT1 antibody such as IgG4 did not increase. These results showed that Th1-biased humoral immune responses against WT1 protein were generated in leukemias and MDS. These results should allow us to consider that Th1-biased cellular immune responses against WT1 protein, which was essentially needed for cancer immunotherapy targeting WT1, should be elicited in patients with hematopoietic malignancies.

Antibody Formation↗
PubMed2005

Basic mechanisms of humoral rejection.

Humoral rejection is among the most vexing problems afflicting organ transplants. Triggered by antibodies predominantly against donor human leukocyte (HLA), humoral rejection can now be understood through consideration of basic mechanisms of immunity to foreign antigens and impact of humoral immunity on blood vessels. Basic considerations may also shed light on mechanisms by which various treatments have recently brought about vastly improved outcomes.

Antibody Formation↗